Available Treatment Options for Patients With Stage-III Resectable NSCLC

Opinion
Video

Alykhan Nagji, MD, provides a brief overview of the landscape surrounding the treatment of patients with stage-III resectable NSCLC.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
2 experts in this video
2 experts in this video
Related Content
Given an unmet need for efficacious therapies against ALK-positive NSCLC, experts discuss optimal ALK TKI sequencing for patients with this disease.

Exploring First-Line ALK Inhibitors, TKI Sequencing in ALK-Positive NSCLC

Roman Fabbricatore
May 21st 2025
Article

Given an unmet need for efficacious therapies against ALK-positive NSCLC, experts discuss optimal ALK TKI sequencing for patients with this disease.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Leticia Nogueira, PhD, MPH
March 31st 2025
Podcast

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

3 Things You Should Know About the Multimodal Treatment of SCLC

3 Things You Should Know About the Multimodal Treatment of SCLC

Lauren Averett Byers, MD;Percy Lee, MD, FASTRO;Erminia Massarelli, MD, PhD, MS
May 19th 2025
Article

Here are 3 things you should know about the multimodal treatment of patients with SCLC.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

HITOCH After Surgery Appears Safe, May Improve Survival in Mesothelioma

HITOCH After Surgery Appears Safe, May Improve Survival in Mesothelioma

Tim Cortese
May 6th 2025
Article

A systematic review shows that patients with mesothelioma who received HITOCH experienced between 13 to 35 months of survival.

“[O]ur findings show that large-scale lung cancer screening is both feasible and effective, and provide a framework for successful delivery of a population-based national program,” according to the study authors.

Low-Dose CT Screening for Lung Cancer Shows Large-Scale Efficacy

Russ Conroy
April 29th 2025
Article

Study data show a small number of individuals with a lung cancer diagnosis within 12 months of a negative baseline screening result.